Skip to content

Effect of Rebound Exercise in Individuals With Type 2 Diabetes

Effect of Rebound Therapy on Metabolic Outcomes and Quality of Life in Nigerian Patients With Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02701569
Enrollment
60
Registered
2016-03-08
Start date
2014-07-31
Completion date
2015-06-30
Last updated
2016-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

The purpose of this study was to investigate the effect of rebound exercise (mini trampoline jumping) on metabolic outcomes and quality of life in patients with Type 2 Diabetes.

Detailed description

The exercise involved jumping on the mini trampoline with feet slightly apart. Participants stood on the mid portion of the trampoline bed and made repeated up-and-down bouncy movements. Each foot strike equals one step or bounce. With each landing, the mat of the trampoline underwent deformation and the springs released the energy stored in them such that the participant was made to bounce off the mat. Exercise was administered for between 10 - 15 minutes after which a 5-minute period of rest was allowed. A heart rate monitor was used to guide the intensity of the exercise in the moderate range. Each participant accumulated between 20 and 30 minutes of rebound exercise (bouncing on a mini trampoline) per session, administered three times per week for 12 weeks. All data were captured at baseline and at the end of the 12-week intervention period.

Interventions

Repeated jumping on a mini trampoline was administered

Sponsors

Aminu Kano Teaching Hospital
CollaboratorOTHER
University of KwaZulu
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* 30- to 60-year-old male and female individuals; * A diagnosis of type 2 diabetes ≤ 5 years; * Attendance at the Diabetes Outpatient Clinics of Aminu Kano Teaching Hospital and Murtala Muhammad Specialist Hospital in Kano, Northwestern Nigeria; * Self-ambulatory; * An inactive lifestyle over the last year.

Exclusion criteria

* A diagnosis of type 2 diabetes for more than 5 years; * Hypertension (systolic and diastolic blood pressure more than 140 and 90 mmHg, respectively) or treatment for hypertension; * Use of insulin therapy * Lower limb weakness and/or deformities with loss of protective sensation in the feet; * Back, shoulder or knee problems and/or joint instability; * History of coronary artery disease, retinopathy and nephropathy; * Myocardial infarction, cardiac or abdominal surgery within the previous 6 months; * History of fractures of the spine, hip, knee and/or ankle joints.

Design outcomes

Primary

MeasureTime frameDescription
Glycated hemoglobin3 monthsGlycated hemoglobin was assessed using the mini-column ion-exchange chromatographic method and expressed in percentage

Secondary

MeasureTime frameDescription
Triglycerides3 monthsTriglycerides (in molar concentration) were enzymatically determined using commercial kits
Fasting plasma glucose3 monthsFasting plasma glucose (in molar concentration) was measured by glucose oxidase assay using a glucose analyzer
Fasting insulin3 monthsFasting insulin (in gravimetric unit) was determined using a commercially available ELISA human insulin kit
High-density lipoprotein cholesterol3 monthsHigh-density lipoprotein cholesterol (in molar concentration) was enzymatically determined using commercial kits
Total cholesterol3 monthsTotal cholesterol (in molar concentration) was enzymatically determined using commercial kits
Low-density lipoprotein cholesterol3 monthsLow-density lipoprotein cholesterol (in molar concentration) was estimated using the Friedewald formula.
Quality of life3 monthsThe short-form 36 health questionnaire was used to assess participants' quality of life and expressed in percentage
Body mass3 monthsBody mass in kilograms was determined using a calibrated weighing scale
Heart rate3 monthsHeart rate was measured in beats per minute using a calibrated electronic device
Respiratory rate3 monthsRespiratory rate (in cycles per minute) was measured by observing and counting the number of times the chest rose in one minute
Blood pressure3 monthsBlood pressure in millimeters of mercury (mmHg) was measured using a calibrated electronic device
Maximal oxygen consumption3 monthsMaximal oxygen consumption in milliliters per kilogram per minute (ml/kg/min) was obtained from exercise stress testing
Diabetes-related emotional distress as measured by the Problem Areas in Diabetes Scale3 monthsDiabetes-related emotional distress was expressed in percentage
Well-Being as measured by the World Health Organization-Well-Being Index3 monthsParticipants' well-being was expressed in percentage
Treatment satisfaction as measured by the World Health Organization-Diabetes Treatment Satisfaction Questionnaire3 monthsScore ranges from 0 (very dissatisfied) to 36 (very satisfied)
Height3 monthsHeight in meters was determined using a stadiometer

Other

MeasureTime frameDescription
Depressive symptoms as measured by the Beck's Depression Inventory3 monthsScore ranges from 0 to 63 with 0 to 13 being minimal and 29 to 63 being severe

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026